A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

A study led by Roswell Park Comprehensive Cancer Center helps explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers ...

For patients with advanced renal cell carcinoma (RCC), there is a sustained clinical benefit with pembrolizumab plus axitinib ...

The approval makes belzutifan the first agent indicated for renal cell carcinoma that has progressed after checkpoint inhibition and a VEGF-TKI. The oral hypoxia-inducible factor (HIF)-2 alpha ...

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic ...

Key Takeaways Current evidence shows limited benefit from additional immunotherapy in renal cell carcinoma patients previously treated with immune checkpoint inhibitors. Two large randomized trials ...

Among patients with locally advanced or metastatic renal cell carcinoma, Fruzaqla (fruquintinib) in combination with sintilimab has been found to slow progression when administered as a second-line ...

The study, which initially led to the FDA approval of lenvatinib plus pembrolizumab for advanced renal cell carcinoma in 2021, continues to provide valuable insights into treatment strategies.

6 Xu H, et al. Fruquintinib Plus Sintilimab in Patients with Treatment‑Naïve and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial.

Notably, advanced renal cell carcinoma patients who have experienced failure with single-agent targeted therapy previously still indicate an unmet medical need.